These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24401540)

  • 41. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
    Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
    Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
    Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
    Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Boorjian SA; Karnes RJ; Viterbo R; Rangel LJ; Bergstralh EJ; Horwitz EM; Blute ML; Buyyounouski MK
    Cancer; 2011 Jul; 117(13):2883-91. PubMed ID: 21692049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
    Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
    Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).
    Yorozu A; Namiki M; Saito S; Egawa S; Yaegashi H; Konaka H; Momma T; Fukagai T; Tanaka N; Ohashi T; Takahashi H; Nakagawa Y; Kikuchi T; Mizokami A; Stone NN
    Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):390-401. PubMed ID: 37802225
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
    Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
    Ishiyama H; Satoh T; Kitano M; Tabata K; Komori S; Ikeda M; Soda I; Kurosaka S; Sekiguchi A; Kimura M; Kawakami S; Iwamura M; Hayakawa K
    J Radiat Res; 2014 May; 55(3):509-17. PubMed ID: 24222312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.
    Peng LC; Narang AK; Gergis C; Radwan NA; Han P; Marciscano AE; Robertson SP; He P; Trieu J; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Greco SC; Tran PT; Deville C; DeWeese TL; Song DY
    Urol Oncol; 2018 Jun; 36(6):309.e7-309.e14. PubMed ID: 29551548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer.
    Takaha N; Okihara K; Kamoi K; Kimura Y; Yamada T; Kawauchi A; Kobayashi K; Yamazaki H; Nishimura T; Miki T
    Urol Int; 2011; 87(1):28-34. PubMed ID: 21701133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Additional androgen deprivation makes the difference: Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy.
    Schiffmann J; Lesmana H; Tennstedt P; Beyer B; Boehm K; Platz V; Tilki D; Salomon G; Petersen C; Krüll A; Graefen M; Schwarz R
    Strahlenther Onkol; 2015 Apr; 191(4):330-7. PubMed ID: 25471276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer.
    Warner A; Pickles T; Crook J; Martin AG; Souhami L; Catton C; Lukka H; Rodrigues G
    Cureus; 2015 Jun; 7(6):e276. PubMed ID: 26180700
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose.
    Martinez A; Galalae R; Gonzalez J; Mitchell C; Gustafson G; Kovacs G
    J Urol; 2003 Dec; 170(6 Pt 1):2296-301. PubMed ID: 14634400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of adding androgen deprivation therapy to permanent iodine-125 implantation with or without external beam radiation therapy on the outcomes in patients with intermediate-risk prostate cancer: A propensity score-matched analysis.
    Sutani S; Yorozu A; Toya K; Shiraishi Y; Nishiyama T; Yagi Y; Nakamura K; Saito S
    Brachytherapy; 2021; 20(1):10-18. PubMed ID: 33069598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.